■ Glaukos Corporation announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 24-month interim analysis of the ongoing 36-month phase 2b clinical trial conducted under a US Investigational New Drug protocol.

Administered during a microinvasive procedure, the iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce IOP, and was designed to continuously release therapeutic levels of the medication for at least 1 year. Once all travoprost is released, the iDose TR was designed to be removed and replaced with a new iDose TR, thus offering an alternative to daily eye drop treatment.